With MarketsandMarkets projecting the global electronic Clinical Outcome Assessments (eCOA) solutions market to grow at compound annual growth rate (CAGR) of 16.1% each year until 2030, it’s clear the eCOA has made its impact within the clinical research landscape. 

Yet despite growing adoption, electronic Clinical Outcome Assessments (eCOA) are still surrounded by misconceptions that hinder their full potential. From concerns about patient usability to assumptions about cost and implementation timelines, these myths can create hesitation among sponsors and research teams alike.

Thus, we’re here to cut through the noise and set the record straight with a summary of a recent webinar featuring speakers from Transcelerate and Medable. 

‍

Oncology research has been on a 20-year rise and is showing no signs of slowing down anytime in the future. Consider this, between 2000 and 2021, the amount of drugs targeting cancer quadrupled. In 2023, a separate research report found that over 2,000 new oncology clinical trials were launched just that year, and that global spending on cancer medicines “is projected to reach $409 billion by 2028.” Finally, as of May 2025, a search of ClinicalTrials.gov yielded over 39,500 studies indexed under terms including “neoplasm,” “cancer,” and “tumor,” encompassing diverse phases and global locations.

Electronic Clinical Outcome Assessments (eCOA) have revolutionized data collection in clinical trials, offering convenience and real-time insights that traditional methods cannot match. 

However, the effectiveness of these digital tools hinges on the quality of the daily experience they offer participants. Read below to see direct feedback from patients and caregivers across multiple conditions in our Patient Champion Network (PCN), as we identify ten critical factors that can improve the eCOA experience.

‍